Overabundant microbiome species: what a high proportion means

Identifying microbes that make up a large share of a sample

An “overabundant species” report flags species or genera whose relative proportion exceeds the laboratory’s comparison range. Depending on the method, it may capture bacteria and possibly other groups, such as fungi. The key word is relative: the report describes the distribution within the sample, not automatically the absolute number of cells in the intestine.

A simple example makes the distinction clearer. If several species decline after antibiotics, the percentage belonging to an unchanged species can rise. That species then looks overrepresented even though it may not have multiplied at all. This shift is different from proven disease-causing overgrowth.

Why dominance means more than one organism’s name

Gut microbes share tasks: they process plant fibers, modify bile acids and produce different metabolites. A community strongly dominated by a few groups may therefore have different capabilities from one with a broader composition. The consequences depend on which organisms and strains are involved.

A population study using two cohorts showed strong relationships between community composition, stool consistency and medication use. Diversity and its possible health associations need to be considered in that context. There is no universal rule that high diversity is always healthy or that low diversity always means disease. Age, diet and intestinal transit also shape composition.

After antibiotics or a major dietary change, bloating and a changed microbiome profile may occur together. The report cannot establish which species is causing symptoms. Skin reactions, histamine-related problems or inflammation, in particular, cannot be inferred from one organism’s dominance. Those questions need appropriately selected investigations.

When this view of the microbiome may be interesting

Major changes such as an infection, new medicines, travel or a period of restrictive eating provide a timeline for interpretation. A report can show that the community had a different composition when the sample was collected. For practical decisions, what matters is whether symptoms are present and whether a treatable cause is suspected.

Some gut inhabitants can become troublesome under particular conditions. These organisms are called pathobionts. Their presence or a higher proportion does not yet establish an infection. Strain, toxin production, resistance, host factors and the location where the organism was found can be important.

A stool profile does not locate small intestinal bacterial overgrowth either. It mainly reflects colon contents. Breath tests investigate a different physiological question and also need careful interpretation. The methods cannot simply be joined into a complete map of every section of the intestine.

Reading a dominance report

Start with the method, reference group and units. Does the report give percentages, absolute quantities or only categories? Which species can it distinguish reliably? Does the method actually capture the fungal groups it claims to assess?

A seemingly balanced profile with several fermenters may describe a broad genetic potential. It does not confirm current production of butyrate, acetate or propionate. Nor does the proportion of Bifidobacterium or Faecalibacterium provide a complete health assessment.

When a few species dominate, consider the direction of the change. Did those organisms actually increase, or did others decline? Was the sample taken soon after antibiotics? Does the reference fit the person being tested? These questions are more useful than assigning microbes to blanket “good” and “bad” categories.

An unusual pattern may add to a clinical discussion. Diet, symptoms and medicines determine which steps make sense. A laboratory flag alone does not justify antimicrobial treatment.

Where the report helps, and where it reaches its limits

A single stool sample reflects a point in time. Bowel preparation, probiotics, infections and shipping conditions can affect the profile. Laboratories use different databases and reference limits. Follow-up measurements are therefore best compared using the same method.

For persistent symptoms, established investigations, such as calprotectin when intestinal inflammation is suspected, may be more useful than another dominance score. Further metabolic or immune tests should address a specific medical question. Assessment aims to understand symptoms and their causes. A more evenly distributed chart is not a treatment goal by itself.

Frequently asked questions

What does an overabundant species test measure?

It compares the abundance of detected microorganisms with a reference. Usually, these are relative proportions derived from DNA data. Without an additional quantitative method, they cannot reliably establish the absolute number of cells belonging to a species.

How is the sample collected?

A small stool sample is collected at home using the supplied system. Clean handling, clear labeling and the required storage conditions matter. Switching collection kits can affect comparisons if preservation and analysis differ.

What does an unusual report say about health?

It shows a composition that differs from the laboratory’s comparison population. Whether the difference matters for health depends on the organism, method and clinical context. The report alone does not explain digestive, skin or metabolic symptoms.

How reliable are the flags?

The measurement depends on sequencing depth, the database and the sample. The category “too high” also depends on the chosen reference. A technical finding can be correct while its clinical significance remains unclear. Reports should distinguish those two levels.

How often should testing be done?

This kind of report does not establish a reason for routine screening. A repeat test may document a particular change, but it should answer a useful question. Without a clear consequence for a decision, more frequent measurement adds little.

Can dominance patterns change quickly?

Yes. Antibiotics, infections and diet can shift relative proportions within days. More stable patterns often take longer to develop. A single high proportion should not be treated as a permanent personal characteristic.

Is overrepresentation a diagnosis?

No. It starts as a statistical description. Diagnosing an infection or another condition requires an appropriate clinical assessment. The word “dysbiosis” in a report does not replace that assessment.

What might be useful after an unusual result?

First clarify the method, the reason for testing and the symptoms. A varied, well-tolerated diet can support general gut health. Prebiotics and probiotics need to be assessed for the particular product and goal. Antibiotics, herbal antimicrobials and strict elimination diets are not automatic consequences of a high relative proportion.

Sources

• Falony G, Joossens M, Vieira-Silva S, Wang J, Darzi Y, Faust K, Kurilshikov A, Bonder MJ, Valles-Colomer M, Vandeputte D, Tito RY, Chaffron S, Rymenans L, Verspecht C, De Sutter L, Lima-Mendez G, D’hoe K, Jonckheere K, Homola D, Raes J (2016). Population-level analysis of gut microbiome variation. Science, 352(6285), 560-564. https://doi.org/10.1126/science.aad3503 PubMed

• Afzaal M, Saeed F, Shah YA, Hussain M, Rabail R, Socol CT, Hassoun A, Pateiro M, Lorenzo JM, Rusu AV, Aadil RM (2022). Human gut microbiota in health and disease: Unveiling the relationship. Frontiers in Microbiology, 13, 999001. https://doi.org/10.3389/fmicb.2022.999001 PubMed

• Fusco W, Lorenzo MB, Cintoni M, Porcari S, Rinninella E, Kaitsas F, Lener E, Mele MC, Gasbarrini A, Collado MC, Cammarota G, Ianiro G (2023). Short-chain fatty-acid-producing bacteria: Key components of the human gut microbiota. Nutrients, 15(9), 2211. https://doi.org/10.3390/nu15092211 PubMed

• Jovel J, Patterson J, Wang W, Hotte N, O’Keefe S, Mitchel T, Perry T, Kao D, Mason AL, Madsen KL, Wong, G. K.-S. (2016). Characterization of the gut microbiome using 16S or shotgun metagenomics. Frontiers in Microbiology, 7, 459. https://doi.org/10.3389/fmicb.2016.00459 PubMed

• Drago L (2025). Navigating microbiome variability: Implications for research, diagnostics, and direct-to-consumer testing. Frontiers in Microbiology, 16, 1580531. https://doi.org/10.3389/fmicb.2025.1580531 PubMed